Piyanuch Kongtim

CONFLICT OF INTEREST STATEMENT Piyanuch Kongtim reports consulting fees from CareDx. The other authors declare no conflicts of interest. DATA AVAILABILITY STATEMENT All data generated or analyzed during this study are included in this published article and its supplementary information files. Supporting Information Filename Description cncr70199-sup-0001-suppl-data.docx8.4 MB Supplementary Material REFERENCES 1. Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354(17): 1813-1826.

Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description ajh27581-sup-0001-Supinfo.docxWord 2007 document , 270.2 KB Data S1. Supporting Information. References 1, , , , and , “Durable Engraftment of Major Histocompatibility Complex-Incompatible Cells After Nonmyeloablative Conditioning With Fludarabine, Low-Dose Total Body Irradiation, and Posttransplantation Cyclophosphamide,” Blood 98, no. 12 (2001): 3456–3464.

CONFLICT OF INTEREST STATEMENT DAL is on the scientific advisory board and receives consulting fees from Avidicure B.V.; receives consulting fees from Catamaran Bio; receives consulting, licensing, and royalty fees from Kiadis Pharma (a Sanofi Company); and has intellectual property interests related to NK cell therapy. Supporting Information Filename Description ajh27281-sup-0001-supinfo.pdfPDF document, 963.7 KB Data S1. Supporting information. REFERENCES 1, , , .